Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
ZIDOVUDINE ALONE OR IN COMBINATION WITH DIDANOSINE OR ZALCITABINE IN HIV-INFECTED PATIENTS WITH THE ACQUIRED-IMMUNODEFICIENCY-SYNDROME OR FEWER THAN 200 CD4 CELLS PER CUBIC MILLIMETER
Autore:
SARAVOLATZ LD; WINSLOW DL; COLLINS G; HODGES JS; PETTINELLI C; STEIN DS; MARKOWITZ N; REVES R; LOVELESS MO; CRANE L; THOMPSON M; ABRAMS D;
Indirizzi:
CARE OF DEYTON L,NIH,60003 EXECUT BLVD BETHESDA MD 20892 ST JOHNS HOSP DETROIT MI 00000 DELAWARE COMMUNITY PROGRAM CLIN RES AIDS WILMINGTON DE 00000 UNIV MINNESOTA,SCH PUBL HLTH,DIV BIOSTAT MINNEAPOLIS MN 55455 NIAID,DIV AIDS,NIH BETHESDA MD 20892 ALBANY MED COLL ALBANY NY 12208 HENRY FORD HOSP DETROIT MI 48202 DENVER COMMUNITY PROGRAM CLIN RES AIDS DETROIT MI 00000 RES & EDUC GRP PORTLAND OR 00000 WAYNE STATE UNIV,MED CTR DETROIT MI 48202 AIDS RES CONSORTIUM ATLANTA ATLANTA GA 00000 COMMUNITY CONSORTIUM SAN FRANCISCO SAN FRANCISCO CA 00000
Titolo Testata:
The New England journal of medicine
fascicolo: 15, volume: 335, anno: 1996,
pagine: 1099 - 1106
SICI:
0028-4793(1996)335:15<1099:ZAOICW>2.0.ZU;2-A
Fonte:
ISI
Lingua:
ENG
Soggetto:
VIRUS-INFECTION; PHASE-I; THERAPY; RESISTANCE; TIME;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Citazioni:
24
Recensione:
Indirizzi per estratti:
Citazione:
L.D. Saravolatz et al., "ZIDOVUDINE ALONE OR IN COMBINATION WITH DIDANOSINE OR ZALCITABINE IN HIV-INFECTED PATIENTS WITH THE ACQUIRED-IMMUNODEFICIENCY-SYNDROME OR FEWER THAN 200 CD4 CELLS PER CUBIC MILLIMETER", The New England journal of medicine, 335(15), 1996, pp. 1099-1106

Abstract

Background We compared two combinations of nucleosides with zidovudine alone in patients with advanced human immunodeficiency virus (HIV) infection. Methods A total of 1102 patients with the acquired immunodeficiency syndrome or fewer than 200 CD4 cells per cubic millimeter wererandomly assigned to receive zidovudine alone or zidovudine combined with either didanosine or zalcitabine. Disease progression, survival, toxic effects, and the CD4 cell response were assessed. Results After a median follow-up of 35 months, disease progression or death occurredin 62 percent of the 363 patients assigned to zidovudine plus didanosine, 63 percent of the 367 assigned to zidovudine plus zalcitabine, and 66 percent of the 372 assigned to zidovudine alone (P=0.24). As compared with zidovudine therapy, treatment with zidovudine plus didanosine was associated with a relative risk of disease progression or death of 0.86 (95 percent confidence interval, 0.71 to 1.03), and treatment with zidovudine plus zalcitabine was associated with a relative risk of 0.92 (95 percent confidence interval, 0.76 to 1.10). Survival was similar in the three groups. In a subgroup analysis, combination therapydelayed disease progression or death in patients who had previously received zidovudine for 12 months or less. Therapy with zidovudine plusdidanosine resulted in more gastrointestinal adverse effects, and treatment with zidovudine plus zalcitabine, more neuropathy. The mean increases in CD4 cell counts at two months were higher with combination therapy than with zidovudine alone. Conclusions In patients with advanced HIV infection, combination therapy with zidovudine and either didanosine or zalcitabine is not superior to zidovudine therapy alone. However, these combinations may be more effective than zidovudine monotherapy in patients with little or no previous zidovudine treatment.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 25/11/20 alle ore 10:24:25